Abstract
Introduction and Objectives: The traditional approach to target a particular receptor is to design compounds that bind to the same site as the endogenous ligand, the so-called "orthosteric site." However, recently the search has shifted to ligands that can interact with a different region of the receptor protein, the "allosteric site," since this approach offers potential pharmacological and therapeutic advantages. The aim of our work was to explore the benzimidazole heterocycle as a novel scaffold for cannabinoid allosterism. Materials and Methods: We synthesized a series of novel benzimidazole-2-carboxamides, analogues of ORG27569, and performed their pharmacological characterization as CB1R allosteric modulators using competitive [3H]-CP55940 and [35S]-GTPγS binding assays. Results: The benzimidazoles 3 and 4 produced significant negative allosteric modulation (NAM) of CP55940 agonism at the mouse CB1R, although are somewhat less potent than the CB1R allosteric cannabinoid ORG27569. Conclusions: Replacing the indole ring with a benzimidazole ring within the structure of ORG27569 abolished the binding of the resultant ligands to CB1R, but the modulation on the agonist-induced GTPγS binding was maintained.
Original language | English |
---|---|
Pages (from-to) | 196-201 |
Number of pages | 6 |
Journal | Cannabis and Cannabinoid Research |
Volume | 1 |
Issue number | 1 |
Early online date | 1 Aug 2016 |
DOIs | |
Publication status | Published - Dec 2016 |
Bibliographical note
Publisher Copyright:© Laura Hernandez-Folgado et al. 2016; Published by Mary Ann Liebert, Inc. 2016.
Acknowledgement: The authors gratefully acknowledge research support from Spanish Grant SAF2012-400075-C02-02 and CAM S2010/BMD-2308. P.M. is recipient of a fellowship JAE-Pre-2010-01119 from “Junta para la Ampliación de Estudios” that is co-financed by FSE.
Keywords
- allosteric modulators
- benzimidazole
- CB receptor
- ORG27569